The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
Front Immunol. 2021 Mar 30;12:652172. doi: 10.3389/fimmu.2021.652172.eCollection 2021.
Raphael Mohr1, Fabian Jost-Brinkmann1, Burcin Özdirik1, Joeri Lambrecht1, Linda Hammerich1, Sven H Loosen2, Tom Luedde2, Münevver Demir1, Frank Tacke1, Christoph Roderburg12
Author information
1Department of Hepatology and Gastroenterology, Charité University Medicine Berlin, Berlin, Germany.
2Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Düsseldorf, Germany.
Abstract
The implementation of immune checkpoint inhibitors (ICI) into the clinical management of different malignancies has largely changed our understanding of cancer treatment. After having proven efficacy in different tumor entities such as malignant melanoma and lung cancer, ICI were intensively tested in the setting of hepatocellular carcinoma (HCC). Here they could achieve higher and more durable response rates compared to tyrosine-kinase inhibitors (TKI), that were sole standard of care for the last decade. Most recently, ICI treatment was approved in a first line setting of HCC, for cases not suitable for curative strategies. However, only a subset of patients benefits from ICI therapy, while others experience rapid tumor progression, worsening of liver function and poor prognosis. Efforts are being made to find immune characteristics that predict tumor responsiveness to ICI, but no reliable biomarker could be identified so far. Nevertheless, data convincingly demonstrate that combination therapies (such as dual inhibition of PD-L1 and VEGF) are more effective than the application of single agents. In this review, we will briefly recapitulate the current algorithms for systemic treatment, discuss available results from checkpoint inhibitor trials and give an outlook on future directions of immunotherapy in HCC.